Leukemia Clinical Trials in Chicago

Showing 1481-1500 of 1,503 trials

Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT00290004

The primary purpose of this study is to evaluate the safety, toxicities, dosage and response rate for an investigational drug, motexafin gadolinium, administered to patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. The secondary purpose of this study is to evaluate the clinical benefit rate, the time it takes for a patient's chronic lymphocytic leukemia or small lymphocytic lymphoma to worsen, the duration of response and the time during which patients survive without chronic lymphocytic leukemia or small lymphocytic lymphoma worsening. Additionally, the patient's response to motexafin gadolinium will be compared to the response of the patient's cells in a laboratory to motexafin gadolinium.

Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaLeukemia+1 more

Pharmacyclics LLC.35 participantsStarted Nov 2005

Los Angeles, California, United States • San Diego, California, United States • Chicago, Illinois, United States +1 more locations

COMPLETEDPhase 22.2 miles

Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia

NCT00116467

The purpose of this study is to evaluate clinical and laboratory safety associated with the administration of GVAX leukemia vaccine and to determine the feasibility of generation of GVAX leukemia vaccine in subjects with acute myelogenous leukemia (AML).

Acute Myelogenous Leukemia

Cell Genesys55 participantsStarted Mar 2001

San Francisco, California, United States • Chicago, Illinois, United States • Baltimore, Maryland, United States +1 more locations

TERMINATEDPhase 22.2 miles

Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)

NCT00061646

The primary objective of this Phase II study is to assess the safety, pharmacokinetics and effectiveness of ABT-510 in combination with standard carboplatin/paclitaxel chemotherapy in subjects with stage IIIb or IV NSCLC.

Carcinoma, Non-Small-Cell Lung

Abbott25 participantsStarted Mar 2003

Miami, Florida, United States • Chicago, Illinois, United States • Memphis, Tennessee, United States +1 more locations

Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia

Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)

Leukemia Trials in Other Cities

Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)

Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease

Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

Amonafide in Combination With Cytarabine in Secondary AML

Pemetrexed Plus Gemcitabine for Patients With Locally Advanced or Metastatic NSCLC Who Have Not Had Previous Chemotherapy.

Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Analgesic Efficacy And Safety of Valdecoxib For Treatment Of Post-Surgical Pain From Bunionectomy Surgery

Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer

Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease

A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer

Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

Study of DN101 and Taxotere in Patients With Advanced Non-Small Cell Lung Cancer

Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer

Other Conditions in Chicago